Skip to main content
OpenTrials
Completed

NCT Number: NCT04900545

Effect of Genetic Polymorphisms on Response to Beta Blocker Therapy in Egyptian Patients

Beta-blockers represent a cornerstone for the treatment of coronary artery disease (CAD). Their protective effect is based on the negative inotropic and chronotropic features, which have been tested in a large number of randomized controlled trials, both in patients with myocardial infarction (MI) and in those with stable angina, demonstrating a reduction of adverse cardiovascular events, a relief of symptoms and a reduction of myocardial ischemia

However, considerable interpatient variability in response to β-blockers has been reported which indicates that a considerable proportion of β-blocker-treated patients do not achieve the warranted cardio protection with β- blockers. This highlights the importance of identifying biomarkers associated with variability in response to β-blockers to improve the current approach for β- blocker selection, which seems to be suboptimal.

This study aims to study the effect of polymorphism in adrenergic beta receptors on beta-blocker response in Egyptian patients.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Acute Coronary Syndrome Cardiovascular Diseases Heart Diseases Hypertension Myocardial Ischemia Vascular Diseases

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Ain Shams University Hospitals.

Cairo, Cairo Governorate, 12234, Egypt

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Beta-blockers naïve patients
  • Patients been on beta-blocker therapy for at least 4 weeks.
  • Age (18-75) Years old.

Exclusion criteria

  • Non-Egyptians.
  • Kidney failure of any stage.
  • Liver failure of any stage.
  • Malignancy.
  • Pregnancy.
  • HR < 55 beats/min (in the absence of b-blocker therapy).
  • Presence of a cardiac pacemaker.

Treatment and study plan

Primary outcomes

  1. Adrenergic receptors genes and blood pressure response to beta-blocker

    Time frame: Three months

    Investigate the association of the adrenergic receptor polymorphisms with reduction in blood pressure (expressed in units of millimeters of mercury "mmHg" ) in the Egyptian patients with acute coronary syndrome on beta blocker therapy.

  2. Adrenergic receptors genes and heart rate response to beta-blocker

    Time frame: Three months

    Investigate the association of the adrenergic receptor polymorphisms with reduction in heart rate (expressed as beats per minute "BPM" ) in the Egyptian patients with acute coronary syndrome on beta blocker therapy.

Sponsors and collaborators

Lead sponsor

Mohamed Saleh Fayed

Other

Registry information

Important dates

Study start
2021
Primary completion
2021
Study completion
2021
First posted
May 25, 2021
Registry last updated
Dec 1, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.